Humira won't have a biosimilar competitor until 2023. Photo: David Phillip / AP

AbbVie and Amgen have agreed to a deal in which Amgen won't start selling Amjevita, a cheaper alternative to Abbvie's blockbuster drug Humira, in the U.S. until 2023. All litigation between the two firms over the drugs also will be dropped, the drug companies said Thursday.

Why it matters: Humira is the top-selling drug in the world. The settlement grants AbbVie another five-plus years of monopoly pricing in the lucrative U.S. market, where drug costs continue to rankle the public. AbbVie released a statement this week saying it will "act responsibly with respect to drug pricing" even though executives recently told investment bankers they may go back to large, multiple price hikes per year.

Correction: AbbVie is granting a license to Amgen, not making payments. Terms of the deal aren't being disclosed.

Go deeper

GAO finds Chad Wolf, Ken Cuccinelli are ineligible for top DHS roles

Photo: CQ-Roll Call, Inc via Getty Images

Acting Homeland Security Secretary Chad Wolf and his acting deputy Ken Cuccinelli are ineligible to be serving in their positions, the Government Accountability Office (GAO) decided in a report released Friday.

Why it matters: While the finding has no immediate power, it could be important evidence in litigation over policies enacted under Wolf and Cuccinelli's leadership, said America's Voice's Ur Jaddou, who served as chief counsel to U.S. Citizenship and Immigration Services (USCIS) under President Obama.

The many divisions over Trump's methane rollback

Illustration: Rebecca Zisser/Axios

EPA's decision to cut regulation of methane is laying bare an oil-and-gas industry divide and setting the stage for political battles this fall and beyond.

Why it matters: Methane is an extremely powerful greenhouse gas and the industry is a key emissions source.

Kushner says Trump didn't promote false Kamala Harris birtherism theory

White House senior adviser Jared Kushner told "CBS This Morning" on Friday that he does not believe President Trump promoted a baseless claim that Sen. Kamala Harris is ineligible to be vice president.

Driving the news: During a press briefing on Thursday, Trump did not question the veracity of a Newsweek op-ed that inaccurately claimed Harris may be ineligible for the office due to her parents' naturalization status at the time of her birth. Harris is an American citizen and was born in Oakland, Calif.